ArticleBMJ open2025
Association of small dense low-density lipoprotein cholesterol with cardiovascular risk in premature acute coronary syndrome and multivessel disease: a single-centre retrospective cross-sectional study.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Prognostic Impact of Metabolic and Inflammatory Risk for Periprocedural MI and Long-Term Events in Three-Vessel Disease Patients.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPremature acute coronary syndrome (PACS) presents with a poor prognosis and significant risks. This study aimed to investigate the association between small-dense low-density lipoprotein cholesterol (sdLDL-C) levels and the severity of coronary lesions, as well as its potential role in risk stratification for PACS patients with multivessel disease (MVD).
designRetrospective cross-sectional study.
settingFirst Affiliated Hospital of Xinjiang Medical University in China, between May 2022 and November 2023.
participants900 PACS patients with MVD confirmed by coronary angiography (CAG) and 600 age-matched and sex-matched controls with normal CAG results.
methodsPatients with PACS and MVD were stratified by the Global Registry of Acute Coronary Events (GRACE) score, and sdLDL-C levels were compared among the different GRACE score groups. The association between sdLDL-C and the GRACE score was evaluated using Pearson's correlation analysis. Multivariate logistic regression analysis was employed to identify factors associated with PACS and MVD. The discriminatory ability of sdLDL-C for PACS with MVD was assessed using receiver operating characteristic (ROC) curve analysis. Restriction cubic spline (RCS) analysis was used to examine the potential nonlinear association between sdLDL-C levels and the high-risk groups of PACS with MVD.
resultsPatients with PACS and MVD exhibited significantly higher sdLDL-C levels compared with control group (p<0.0001). Multivariate logistic regression analysis identified elevated sdLDL-C as an independent factor associated with PACS and MVD (OR =1.327; 95% CI =1.258 to 1.400; p<0.0001). The area under the curve (AUC) for sdLDL-C in discriminating PACS with MVD was 0.846 (95% CI=0.826 to 0.866, with a sensitivity of 94.7% and specificity of 58.0%). Furthermore, sdLDL-C levels were significantly higher in the high-risk group than in the low-moderate risk groups (p<0.0001). A strong positive association was observed between sdLDL-C levels and the GRACE score (r=0.644; p<0.0001). The AUC of sdLDL-C for discriminating high-risk cases of PACS with MVD was 0.841 (95% CI=0.815 to 0.867, with sensitivity of 94.3% and specificity of 62.3%). The RCS curve revealed a significant nonlinear association between increasing sdLDL-C levels and the high-risk groups of PACS with MVD (p value for nonlinearity=0.006).
conclusionsElevated sdLDL-C levels demonstrated a significant association with the risk of PACS and MVD. These findings indicate sdLDL-C may serve as a potential biomarker for risk stratification in this high-risk population. However, causal inferences require validation in prospective studies. TRIAL REGISTRATION NUMBER: ChiCTR2300074166.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.